GÖTTINGEN, Germany,
Sept. 4, 2021 /PRNewswire/ -- The
life science group Sartorius will be admitted to the German DAX
blue chip index. After the market closes on September 17, 2021, Sartorius preference shares
will be included in the calculation of the DAX, as Deutsche Börse
announced on Friday evening. In addition, Sartorius preference
shares will continue to be listed on the TecDAX, the leading index
of the German technology stocks.
"Sartorius has been performing very dynamically. Based on its
customer focus, innovation, and sustainable profitable growth, our
company has been creating value for customers, employees, and
investors alike, and we would like to thank all of these
stakeholders for their many years of trust. We are now pleased that
the performance of our shares has resulted in their inclusion in
the DAX. At the same time, we are aware that share price
development also depends on market factors that we cannot
influence. Membership in the DAX shows the increasing importance of
the biotech and life science sectors and puts Sartorius even more
in the public eye. Last but not least, it gives us greater
visibility as an employer," said Joachim
Kreuzburg, Executive Board Chairman and CEO of
Sartorius.
Deutsche Börse had decided on various rule changes for its
indices at the end of 2020 and announced that it would expand the
DAX index from 30 to 40 members. Following this reform, the DAX
will comprise the 40 largest companies traded on Deutsche
Börse based on their free-float market capitalization. Accordingly,
once the Sartorius shares that are not freely tradable are
deducted, approximately 72 percent of its preference shares will be
included in this index, while the ordinary shares will not be
considered in the calculation. Thus, approximately one-third of
Sartorius' total market capitalization will be taken into account
for determining membership in the DAX.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a
leading international partner of life science research and the
biopharmaceutical industry. With innovative laboratory instruments
and consumables, the Group's Lab Products & Services Division
concentrates on serving the needs of laboratories performing
research and quality control at pharma and biopharma companies and
those of academic research institutes. The Bioprocess Solutions
Division with its broad product portfolio focusing on single-use
solutions helps customers to manufacture biotech medications and
vaccines safely and efficiently. The Group has been annually
growing by double digits on average and has been regularly
expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
Follow Sartorius on Twitter and on LinkedIn.
Contact
Timo
Lindemann
Corporate Communications
+49 (0)551.308.4724
timo.lindemann@sartorius.com
Logo -
https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/sartorius-to-join-the-dax-blue-chip-index-301369378.html
SOURCE Sartorius AG